B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.

Background: Osteosarcoma (OS) mainly happens in children and youths. Surgery, radiotherapy and chemotherapy are the common therapies for osteosarcoma treatment but all their anti-tumor effects are limited. In recent years, a new cellular therapy, CAR-T, a cellular immunotherapy with genetically engineered T cells bearing chimeric antigen receptor targeting specific tumor-associated antigen, has been proved to be an effective therapy against acute lymphoblastic leukemia.

Fate, source and mass budget of sedimentary microplastics in the Bohai Sea and the Yellow Sea.

As reservoirs for pollutants transported via the Yangtze and Yellow Rivers, the Bohai Sea (BS) and Yellow Sea (YS) play an important role in transporting microplastics (MPs) to the Pacific Ocean. The fate, sources and mass budget of MPs in the BS and the YS were investigated by Pearson correlation, principal component analysis-multilinear regression analysis (PCA-MRLA) and a mass balance model to sedimentary MPs data. Average MP abundances were 137 and 119 items kg in the Bohai and Yellow Seas, respectively.

Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.

Chimeric antigen receptor (CAR) T cells have been successfully used for the treatment of hematological malignancies including acute and chronic lymphoblastic leukemia. However, results of CAR T cell projects in solid tumors have been less impressive to date, partly because of immunosuppressive tumor microenvironment (TME). It is widely known that high adenosine production is an important factor causing tumor-induced immunosuppression in TME, and adenosine mediates the suppression of anti-tumor T cell responses via binding and signaling through adenosine 2a receptor (A2aR).

Three-dimensional covalent organic frameworks based on a π-conjugated tetrahedral node.

The construction of three-dimensional (3D) covalent organic frameworks (COFs), especially fully conjugated 3D COFs, is a long-standing challenge. Herein, we report a saddle-like, π-conjugated cyclooctatetrathiophene (COTh) as a tetrahedral node to construct fully conjugated 3D COFs. The present work enriches the structural diversities and potential applications of 3D COFs.

A non-planar 2D covalent organic framework derived from a Z-shaped building unit.

Herein, a novel non-planar 2D COF with a stair-stepped structure was constructed from a Z-shaped building block for the first time. Compared with its similar planar COF, the unique stair-stepped non-planar COF possesses larger surface area and stronger fluorescence, which was further applied for specific explosive detection through a fluorescence quenching mechanism. This work not only extends the traditional planar 2D COF structures to unique non-planar structures based on the bottom-up design principle, but also expands the potential applications of COF materials.

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.

Since the approval of chimeric antigen receptor (CAR) T cell therapy targeting CD19 by the FDA, CAR-T cell therapy has received increasing attention as a new method for targeting tumors. Although CAR-T cell therapy has a good effect against hematological malignancies, it has been less effective against solid tumors. In the present study, we selected mesothelin (MSLN/MESO) as a target for CAR-T cells because it is highly expressed by solid tumors but only expressed at low levels by normal tissues.

Detection of residual E. coli host cell DNA by 23S ribosomal RNA gene-targeted quantitative polymerase chain reactions.

Among the many systems available for heterologous protein production gram-negative bacterium Escherichia coli (E. coli) has long been widely used because of its ability to grow rapidly with a high density on inexpensive substrates. The use of E.

PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.

Chimeric antigen receptor T (CAR T) cell therapy is a new pillar in cancer therapeutics, and has been successfully used for the treatment of cancers, including acute lymphoblastic leukemia and solid cancers. Following immune attack, many tumors upregulate inhibitory ligands which bind to inhibitory receptors on T cells. For example, the interaction between programmed cell death protein 1 (PD-1) on activated T cells and its ligands (widely known as PD-L1) on a target tumor limits the efficacy of CAR T cells therapy against poorly responding tumors.